View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
May 6, 2013

STAT-Diagnostica completes $17m financing round to develop diagnostic systems

Spain-based STAT-Diagnostica has completed financing worth $17m to finalise the development of its Near Patient Testing diagnostic systems, and clinical validation of its first products.

By admin-demo

Spain-based STAT-Diagnostica has completed financing worth $17m to finalise the development of its Near Patient Testing diagnostic systems, and clinical validation of its first products.

Near Patient Testing systems being developed by the company, including a novel in-vitro diagnostic system, are claimed to simplify the process and provide results in less than 30 minutes for the diagnosis of some medical conditions.

The new Series B financing round is believed to support the company’s preparation for European market launch scheduled for 2015.

"Near Patient Testing systems being developed by the company, including a novel in-vitro diagnostic system, are claimed to simplify the process and provide results in less than 30 minutes for the diagnosis of some medical conditions."

STAT-Diagnostica CEO and co-founder Jordi Carrera said; "Our ability to close the round is proof of the outstanding team behind the company, and demonstrates the potential of our technology in the fast growing decentralised diagnostics market."

Besides offering multi-analyte and multi-sample capabilities, STAT-Diagnostica’s platform is said to enhance clinical decision making by medical practitioners and deliver improved patient management, benefiting the healthcare system with direct and indirect savings.

On of financing, the company proposes to direct all the first clinical applications at infectious disease detection, antibiotic resistance determination and detection of biomarkers in critically ill patients.

A new investor, Kurma Life Sciences Partners, has led the financing round, which involved participation from other new investors, including Idinvest; Boehringer Ingelheim Venture Fund and Caixa Capital Risc; alongside existing investors Ysios Capital and Axis.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU